Pancreatic adenocarcinoma (PAC) is associated with extremely poor prognosis and remains
a lethal malignancy. The main cure for PAC is surgical resection. Further treatment …

Chimeric antigen receptors (CAR) are synthetic receptors that target T cells to cell-surface
antigens and augment T-cell function and persistence. Mesothelin is a cell-surface antigen …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional
treatments, although a limited number of early-stage patients can undergo radical resection …

Over three decades have passed since the first report on the expression of CA125 by
ovarian tumors. Since that time our understanding of ovarian cancer biology has changed …

The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive
antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor …

Mesothelin is a tumor antigen that is highly expressed in many human cancers, including
malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an …

Translating the recent success of chimeric antigen receptor (CAR) T cell therapy for
hematological malignancies to solid tumors will necessitate overcoming several obstacles …

Purpose: Adoptive T-cell immunotherapy with tumor infiltrating lymphocytes or genetically-
modified T cells has yielded dramatic results in some cancers. However, T cells need to …

Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the
body's mesothelial surfaces, but significantly overexpressed in a broad range of solid …

We have recently reported that an immunotoxin targeting mesothelin produced durable
major tumor regressions in patients with extensive treatment-refractory mesothelioma. These …